Effect of different loading doses of atorvastatin on percutaneous coronary intervention for acute coronary syndromes

Canadian Journal of Cardiology

Volumn 26, Issue 9, 2010, Pages 481-485

  Sun, Yujiao ^a   Qi, Guoxian ^a   Gao, Yuan ^a   Zhang, Haishan ^a   Pang, Xuefeng ^a   Zhao, Weihua ^a   Zhang, Zixin ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Atorvastatin; Interventional therapy; Non ST segment elevation acute coronary syndrome

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CLOPIDOGREL; CREATINE KINASE MB; DIISOPROPYLAMINE DICHLOROACETATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; LOW MOLECULAR WEIGHT HEPARIN; TROPONIN I;

ACUTE CORONARY SYNDROME; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART MUSCLE INJURY; HUMAN; HUMAN TISSUE; INCIDENCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYALGIA; MYASTHENIA; NAUSEA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VOMITING;

EID: 78549281829     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(10)70452-9     Document Type: Article

References (20)

1. Ellis SG, Chew D, Chan A, et al. Death following creatine kinase-MB elevation after coronary intervention: Identification of an early risk period: Importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation 2002;106:1205-10.
2. Pasceri V, Patti G, Nusca A, et al. ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: Results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) study. Circulation 2004;110:674-8.
3. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: Results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007;49:1272-8.
4. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: Results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 2009;54:558-65.
5. Thygesen K, Alpert JS, White HD, on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. J Am Coll Cardiol 2007;50:2173-95.
6. Nallamothu BK, Bates ER. Periprocedural myocardial infarction and mortality: causality versus association. J Am Coll Cardiol 2003;42:1412-4.
7. Ray KK, Cannon CP, Ganz P. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndomes trials? Am J Cardiol 2006;98:S18-25.
8. Calabro P, Yeh ET. The pleiotropic effects of statins. Curr Opin Cardiol 2005;20:541-6.
9. Wassmann S, Faul A, Hennen B, et al. Rapid effect of 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibition on coronary endothelial function. Circ Res 2003;93:e98-103.
10. Hinoi T, Matsuo S, Tadehara F, et al. Acute effect of atorvastatin on coronary circulation measured by transthoracic Doppler echocardiography in patients without coronary artery disease by angiography. Am J Cardiol 2005;96:89-91.
11. Sanguigni V, Pignatelli P, Lenti L, et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 2005;111:412-9.
12. Macin SM, Perna ER, Farias EF, et al. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: Results of a randomized, double-blind, placebo-controlled study. Am Heart J 2005;149:451-7.
13. Patti G, Chello M, Pasceri V, et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: Results from the RMYDA-CAMs (Atorvastatin for Reduction of Myocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol 2006;48:1560-6.
14. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 2003;41:508-15.
15. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL Study. A randomized controlled trial. JAMA 2001;285:1711-8.
16. Cannon CP, I Braunwald E, McCabe C, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Eng J Med 2004;350:1495-504.
17. Piorkowski M, Fischer S, Stellbaum C, et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: Is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol 2007;49:1035-42.
18. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholosterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Tteatment Panel III) final report. Circulation 2002;106:3143-421.
19. Ge J, Kin YJ, Jang YS, et al. Design and rationale of a study in Asia of atorvastatin pretreatment in patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndromes. J Cardiol 2010;55:303-8.
20. Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol 2007;99:410-4.